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TransplantatABSTRACT
Introduction. Single or bilateral lung transplantation is a therapeutic procedure for end-
stage lung diseases. In particular, in cases of chronic obstructive pulmonary disease
(COPD) and pulmonary fibrosis, patients can be referred to the transplant center late and
with important comorbilities. Pulmonary hypertension (PH) associated with lung diseases
not only is an index of poor outcome but also is an indication for bilateral procedure.
Methods. We conducted a retrospective observational study. We analyzed right heart
catheterization in a consecutive series of patients who underwent lung transplantation from
2006 to 2014 for end-stage COPD and pulmonary fibrosis.
Results. We included in the study 73 patients (35 with fibrosis and 38 with COPD);
prevalence of PH was higher in the COPD group (84.3% vs 31.4%), and with worse he-
modynamic parameters (mean pulmonary artery pressure [30.3 mm Hg vs 24.1 mm Hg]).
The majority of COPD patients presented mild or moderate PH, and fibrosis patients
showed normal pulmonary arterial pressures.
Conclusions. COPD patients are referred to the Transplant Center with a higher prev-
alence of PH because of an echocardiographic screening or a late referral, but many pa-
tients survive on the waiting list and undergo the procedure. On the other hand, patients
transplanted with interstitial diseases have a lower prevalence of PH; this can be explained
by an earlier referral or a higher mortality on the waiting list and a more aggressive and
rapidly progressing disease.P.S. and F.P. contributed equally to this study and share the
first authorship.
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3, 10126, Turin, Italy. E-mail: psolidoro@cittadellasalute.to.itPULMONARY HYPERTENSION (PH) is defined as amean pulmonary arterial pressure (mPAP) higher
than 25 mmHg, as measured by right heart catheterization
(RHC) at rest [1]. Pulmonary arterial hypertension (PAH)
and pulmonary venous hypertension (PVH) are tradi-
tionally distinguished on the basis that PAH patients have
a pulmonary wedge pressure (PWP) lower than 15 mm Hg.
In 2008, the Dana Point Symposium on Pulmonary Hy-
pertension classified chronic obstructive pulmonary dis-
ease (COPD)eassociated PH into Group 3, “Pulmonary
hypertension associated with lung disease and/or hypox-
emia” [2]. COPD is defined in terms of airflow obstruction
that results from an inflammatory process affecting the
airways and lung parenchyma. Different inflammatorylsevier Inc. All rights reserved.
enue South, New York, NY 10010-1710
ion Proceedings, 47, 2161e2165 (2015)mediators can have local and systemic activities and clin-
ical consequences [3,4]. Changes in pulmonary vessels
represent an important component of the disease. Alter-
ations in vessel structure are very common, and abnor-
malities in their function impair gas exchange and result in
PH [5]. Hurdman et al., in a recent article [6], have studied
the characteristics and outcomes, in particular mortality,0041-1345/15
http://dx.doi.org/10.1016/j.transproceed.2015.01.031
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Table 1. Demographic Data
Fibrosis COPD P
No. of patients 35 38
Mean age (SD) 56 (8.9) 57 (7.6)
Gender male/female 26/9 28/10
Mean BMI 26.98 24.52
Ex smokers n. (%) 20 (57%) 32 (84%)
Systemic arterial hypertension
n. (%)
10 (28%) 19 (50%)
History of coronary arterial
disease n. (%)
4 (11%) 2 (5%)
Diabetes n. (%) 8 (22%) 2 (5%)
Osteopenia/osteoporosis n. (%) 13 (37%) 11 (28%)
Obstructive sleep apnea
syndrome n. (%)
4 (11%) 2 (5%)
Mean %FEV1 (SD) 55.1 (19.6) 26.5 (10.7)
Mean %FVC (SD) 54.4 (18.9) 65.8 (17.5)
Mean %DLCO (SD) 26.6 (7) 32.2 (19.9) n.s.
Mean PaO2 (SD) (in mm Hg) 56.1 (8.4) 55 (8.5) n.s.
Mean PaCO2 (SD) (in mm Hg) 41.8 (5) 44.7 (7.8) n.s.
Mean %6MWT distance
(SD) (in m)
48.7 (3.6) 45.9 (2.6) n.s.
Percentages refer to the total group population.
Abbreviations: COPD, chronic obstructive pulmonary disease; BMI, body
mass index; FEV1, 1-second forced expiratory volume; FVC, forced vital ca-
pacity; DLCO, diffusion lung capacity for carbon monoxide; %6MWT, percent of
the predicted distance at 6 minute walking test; n.s., not significant.
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COPD over a 9-year period. Survival has been studied on
the basis of mPAP, age, diffusion lung capacity for carbon
monoxide (DLCO), mixed venous oxygen saturation
(SvO2), and World Health Organization functional class.
For all the parameters studied the patients were divided
into 2 groups. In particular, in those with severe PH-COPD
(mPAP > 40 mm Hg), 1-year survival was 70% and 3-year
survival was 33%, which is significantly worse than the 83%
and 55%, respectively, seen in mildemoderate PH-COPD
(mPAP < 40 mm Hg).
In pulmonary fibrosis there is only a poor or even no
correlation between PH severity and either lung function
impairment [7] or high-resolution CT fibrosis score [8].
Increased dyspnea, deterioration of gas exchange at rest,
low DLCO values, rapid desaturation during exercise, high
brain natriuretic peptide (BNP) levels, gross right heart
dilation on chest radiography, and limitation of exercise
capacity caused by circulatory impairment have been linked
to PH development in idiopathic pulmonary fibrosis (IPF)
[9e11]. Doppler-defined PH (systolic PAP > 50 mm Hg)
and even invasive mPAP values > 17 mm Hg [10] were
associated with impaired survival in IPF, with mPAP and
forced vital capacity (FVC) as independent predictors of
survival [11]. Rapid progression of PH was reported in late-
stage diffuse parenchymal lung disease (DPLD)/IPF pa-
tients [12]. In some studies, the prognosis of PH in lung
fibrosis is not linked to the mPAP values but to pulmonary
vascular resistance [13] or cardiac index (CI), with CI
values < 2.4 L/min/m2 correlated to survival of only a few
months [14]. Assessment and definition of PH due to
chronic lung diseases is a fundamental step in end-stage
lung diseases (Group 3). Echocardiography is the initial
modality for noninvasive diagnosis of PH in COPD and
DPLD. Comparing echocardiographic data with RHC data
in patients affected by lung diseases, positive predictive
values of 32% and 68%, respectively, and negative predic-
tive values of 93% and 67%, respectively, were reported
[14,15]. Plasma levels of BNP or the N-terminal pro-
hormone of BNP are elevated in severe COPD- and DPLD-
associated PH, but their low sensitivity in moderate PH may
be confounded by left heart abnormalities [16]. Neverthe-
less, BNP levels were found to be strongly predictive of
mortality in a mixed DPLD population [17]. RHC, consid-
ered the gold standard for PH diagnosis, should be per-
formed in patients with chronic lung disease when: 1)
evaluation for lung transplantation is deemed necessary; 2)
clinical worsening and progressive exercise limitation is
disproportionate to ventilatory impairment; 3) progressive
gas exchange abnormalities are disproportionate to venti-
lator impairment; 4) an accurate prognostic assessment is
deemed to be critical; 5) severe PH is suspected by nonin-
vasive measures and further therapy or inclusion in clinical
trials or registries are being considered; and 6) there is
suspicion of left ventricular systolic/diastolic dysfunction
and categorization of the pulmonary artery occlusion pres-
sure might alter management [18,19].The aim of this study was to define the prevalence of
PH in 2 populations who will undergo lung trans-
plantation (COPD and pulmonary fibrosis patients) at the
transplantation center referral. As a secondary objective
we evaluated differences in hemodynamic parameters
between these 2 groups.METHODS
We conducted an observational retrospective study; we studied RHC
in a consecutive cohort of patients who underwent lung trans-
plantation from 2006 to 2014 for COPD and pulmonary fibrosis.
Through the analysis of the corresponding medical records, for each
patient the following information was gathered: demographics, body
mass index, smoking habits, presence of comorbidities (coronary
artery disease, systemic arterial hypertension, osteopenia/osteopo-
rosis, diabetes, obstructive sleep apnea syndrome), arterial blood gas
analysis, spirometric functional data (1-second forced expiratory vol-
ume [FEV1], forced vital capacity [FVC], DLCO) and 6-minute
walking test distance performed (percentage of the predicted value,
in accord with the Enright equation).
During the pretransplantation evaluation, all patients underwent
RHC. The femoral or jugular venous approach was used for RHC.
Cardiac output (CO) and CI were calculated by saturation measure-
ment according to the Fickmethod. pulmonary artery pressure (PAP),
pulmonary wedge pressure (PWP), right ventricular pressure, and
right atrial pressure were measured during breath hold at baseline
over at least 3 heart cycles. Mean pulmonary artery pressure was
calculated by integration of the pressure curve using Metek software
(Metek GmbH, Roetgen, Germany). Pulmonary vascular resistance
was derived from pulmonary vascular resistance ¼ (mean pulmonary
artery pressure pulmonary capillary wedge pressure)/cardiac output.
Diagnosis of PAH was made in accord with international
guidelines [20]. We collected the following RHC data: systolic PAP,
Table 2. Prevalence of mPAP in the 2 Populations
mPAP (in mm Hg) Fibrosis COPD
<25 n. 24 6 30
Normal % 68.6 15.8 41.1
25mPAP<35 n. 6 22 28
Mild % 17.1 57.9 38.6
35mPAP<45 n. 4 8 12
Moderate % 11.4 21.1 16.4
45 n. 1 2 3
Severe % 2.9 5.3 4.1
Division of mPAP values in 4 groups: normal, mild, moderate, and severe.
Percentages refer to the total group population.
Abbreviations: mPAP, mean pulmonary arterial pressure; COPD, chronic
obstructive pulmonary disease.
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vascular resistances. Values of mPAP were divided into 4
categories: <25 mm Hg (normal), 25 to 35 mm Hg (mild PH), 35 to
45 mm Hg (moderate PH), >45 mm Hg (severe PH) [21]. A further
speculative division of mPAP values provided 6 categories
[22,23]: <25 mm Hg, 25 to 29 mm Hg, 30 to 34 mm Hg, 35 to39 mm
Hg, 40 to 44 mm Hg, and 45 mm Hg.
Comparison between the groups of patients with pulmonary fibrosis
and the group with COPDwere conducted using the Student t test for
continuous outcome variables such as DLCO, CO, continuousmPAP.
Pearson c2 tests were used for categorical outcome variables such as
categories of mPAP.Table 3. Prevalence of mPAP in the 2 Populations
mPAP (in mm Hg) Fibrosis COPD
<25
n. 24 6 30
% 68.6 15.8 41.1
25mPAP<29
n. 4 12 16
% 11.4 31.5 21.9
30mPAP<35
n. 2 10 12
% 5.7 26.3 16.4
35mPAP<40
n. 1 6 7
% 2.8 15.7 9.5
40mPAP<45
n. 3 2 5
% 8.5 5.2 6.8
45
n. 1 2 3
% 2.8 5.2 4.1
Division of mPAP values in 6 groups. Percentages refer to the total group
population.
Abbreviations: mPAP, mean pulmonary arterial pressure; COPD, chronic
obstructive pulmonary disease.RESULTS
We retrospectively analyzed data of 73 patients; 35 of them
belonged to the fibrosis group and 38 to the COPD group.
Demographic and functional data are shown in Table 1. The
fibrosis population had a higher prevalence of patients
affected by osteopenia/osteoporosis or diabetes than the
COPD one. On the contrary, COPD patients had a higher
prevalence of smoking history and systemic arterial hyper-
tension. We did not find any difference in PaO2, PaCO2,
DLCO, and 6-minute walking test distance data between the
2 groups of patients. We did not search any difference in
FEV1 and FVC values because the 2 leading pathologies
had different functional spirometric characteristics.
On the basis of mPAP value, we first divided patients in 4
groups: <25 mm Hg (normal), 25 to 35 mm Hg (mild PH),
35 to 45 mm Hg (moderate PH), >45 mm Hg (severe PH)
(21). There was evidence of difference between groups
(P < .0001): in particular, the majority of fibrosis patients
presented normal PAPm values (68.6% of them) and the
PH prevalence was 31.4%; on the other hand, PH preva-
lence in COPD patients was 84.3% (57.9% had a mild,
21.1% a moderate, and 5.3% a severe PH) (data shown in
Table 2). Secondly, we divided PAPm values into 6
groups: <25 mm Hg, 25 to 29 mm Hg, 30 to 34 mm Hg, 35
to 39 mm Hg, 40 to 44 mm Hg, and 45 mm Hg. In this
subdivision, there also was evidence of difference between
groups (P < .001); COPD patients had PAPm values be-
tween 25 and 29 mmHg in 31%, between 30 and 34 mmHg
in 26%, and between 35 and 39 mm Hg in 15% of
cases. These data confirmed that in fibrosis, values ofmPAP> 25 mmHg are equally distributed in all remaining
5 categories (Table 3).
Fibrosis and COPD RHC data are shown in Table 4.
COPD patients presented with higher dPAP (P < .005),
mPAP (P < .001), PWP (P < .05), and total pulmonary
vascular resistances (P < .01) than the fibrosis group.DISCUSSION
The prevalence of PH in the general COPD population is
undefined because stable COPD patients do not routinely
undergo RHC.Most studies published on this topic focus on
patients with moderate to severe disease awaiting lung
transplantation because hemodynamic data from cardiac
catheterization are part of the standard transplant evalua-
tion. These studies revealed that PH is common in advanced
COPD. One of these studies evaluated patients with func-
tionally very severe COPD (mean FEV1 <27% predicted)
using a cutoff for definition of PH of a mPAP higher than 20
mm Hg; they found that 90.8% of those patients had PH.
The majority (61.4%) of them had an elevated PWP (higher
than 12 mm Hg), suggesting the cause of their PH was
related, at least in part, to underlying cardiac abnormalities
[22]. A second study followed up 215 patients evaluated for
lung volume reduction surgery or lung transplantation
(mean FEV1 24% predicted). Using a conventional defi-
nition of PH (mPAP >25 mm Hg), and excluding patients
with elevated PWP, the prevalence of PH was 50.2% [23].
The largest study to date evaluated 4930 patients listed for
lung transplantation with the primary diagnosis of COPD.
Pulmonary hypertension was defined using World Health
Organization Group 1 PAH criteria (mPAP >25 mm Hg
with PWP <15 mm Hg) and pulmonary venous hyperten-
sion as mPAP 25 mmHg with PWP more than 15 mm Hg.
Table 4. Hemodynamic Parameters in the 2 Populations
Hemodynamic parameters Fibrosis COPD P
Mean sPAP (SD) (in mm Hg) 41.1 (18.8) 43.1 (12.4) n.s.
Mean dPAP (SD) (in mm Hg) 15.9 (8.2) 22.2 (7.7) <.005
Mean mPAP (SD) (in mm Hg) 24.1 (8.2) 30.3 (6.9) <.001
Mean PWP (SD) (in mm Hg) 10.1 (0.8) 13.7 (1.1) <.05
Mean CO 6.3 (1.6) 6.2 (2.5) n.s.
Mean CI 3.3 (0.6) 3.7 (1.1) n.s.
Mean total pulmonary
vascular resistances
4 (2) 5.5 (2) <.01
Abbreviations: mPAP, mean pulmonary arterial pressure; sPAP, systolic pul-
monary artery pressure; dPAP, diastolic pulmonary artery pressure; mPAP,
mean pulmonary artery pressure; CO, cardiac output; CI, cardiac index.
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31%, with an additional 17% having PVH [24]. Several
studies in patients with previous GOLD (Global Initia-
tive for Chronic Obstructive Lung Disease) stage IV
showed that up to 90% of these patients have a mPAP of
>20 mm Hg, with most ranging between 20 and 35 mm
Hg and about 3% to 5% of patients with mPAP >35 to
40 mm Hg [25]. In our experience, the prevalence of PH
in COPD patients was 83.5% and is in line with litera-
ture data; in particular, the majority of the COPD
population presented mPAP values consistent with mild
PH. As reported in the literature, our population also
had very compromised lung function with a severe de-
gree of bronchial obstruction (mean FEV1 26.5%) and
hypoxemia at rest (PaO2 55 mm Hg) but, considering the
functional impairment (DLCO, distance achieved during
6-minute walking test, PaO2, PaCO2), no differences
with the fibrosis group were reported. Compared with
the literature, we reported a lower percentage of COPD
patients with PWP >15 mm Hg (18%).
In interstitial lung diseases, international guidelines sug-
gest that PAP values are the most important predictor of
mortality [10]. In the literature, the prevalence of PH in
patients affected by IPF ranges from 8% to 21%, but higher
percentages (30% to 50%) are found in advanced and end-
stage cases [19,26]. Among those patients, a few may pre-
sent with mPAP values >40 mm Hg [7]. Our results confirm
these assumptions because the prevalence of PH in the
fibrosis group in our study is 31.4%, and only 11.3% of them
presented with mPAP <40 mm Hg.
The study of right heart pressure is really fundamental when
a patient is evaluated for a lung transplantation, as we have to
answer at least 2 questions: “is it the correct time?” and “What
is the correct procedure (single or double lung transplant)?”
The correct timing inCOPD is given in particular by theBODE
index [27,28], but the presence of PH is a mandatory indication
[29]; moreover, the choice of procedure in COPD [30] and in
fibrosis [31] is yet an open debate, because new procedures of
organ procurement are now available (ie, ex vivo lung reper-
fusion and noneheart-beating donors) [32e35].
A remarkable problem in intensive care units is the
postsurgical management in cases of a single procedure in
COPD: in fact in PH-COPD patients immediately aftertransplantation almost all the blood flow is directed to the
transplanted lung with high risk of reperfusion syndrome,
while all the ventilation is directed to the more compliant
lung (native COPD lung) but with low perfusion. In cases of
reperfusion edema, we run the risk of having a transplanted
lung perfused and unventilated and a native COPD lung
ventilated but unperfused. The mPAP value used as cut-off
to choose the procedure is conventionally 30 to 35 mm Hg,
but this is an empirical behavior that needs more data [36].
In our study, there was a difference in hemodynamic values
between 2 populations, with worse data for the COPD one.
Possible explanations may be the following: 1) some severe
COPD patients referred to transplant centers have two
different diseases: a common (COPD) and a rare one
(PAH); 2) PH is an indication for lung transplant in COPD,
and patients with echocardiographic suspected disease are
referred to transplant centers earlier; 3) other patients are
referred to transplant centers too late with higher PH, very
poor outcome, and a progressive disease; 4) patients with
COPD and PH have worse symptoms (dyspnea) and a poorer
quality of life, and clinicians are more prone to refer to a
transplant center.
On the other hand, patients with interstitial lung diseases
undergoing lung transplant have a lower prevalence of PH at
RHC evaluation. These data have different possible expla-
nations: 1) patients with pulmonary fibrosis have such a poor
quality of life and shortness of breath that they are referred to
transplantation centers before the development of PH; 2)
patients with PH associated with interstitial diseases are so
clinically and functionally compromised that they die on the
waiting list before having a surgical opportunity; 3) PH leads
to a higher risk of death on the waiting list because of an
obligatory procedure choice (bilateral lung transplant), to
avoid reperfusion syndrome, that limits the pool of donors.
Moreover, the bilateral procedure cannot be proposed for
older patients; this limits both the number of potential re-
cipients and, in the case of good donors, the number of patients
undergoing lung transplantation with a single lung procedure.
CONCLUSIONS
Clinical symptoms and physical signs of PH may be difficult
to identify in patients affected by respiratory disorders.
COPD and diffuse parenchymal lung diseases, including
IPF, are associated with a high prevalence of PH. In our
center, during routine pretransplantation evaluation, the
RHC revealed a higher prevalence of PH in COPD patients.
On the contrary, the prevalence is lower in cases of fibrotic
disease, and the majority of patients have normal mPAP
values. A careful evaluation of clinical and hemodynamic
data is mandatory because it may influence the prognosis of
patients and the type of surgical approach.
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